Stifel, CRWD and CrowdStrike
Rhumbline Advisers trimmed its holdings in shares of Stifel Financial Corp. (NYSE:SF – Free Report) by 2.8% during the fourth ...
Stifel analyst Paul Matteis lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $38 from $45 and keeps a Hold rating on the ...
Barry Bannister, Stifel chief equity strategist, joins CNBC's 'Squawk on the Street' to discuss market outlooks for 2025.
DraftKings (NASDAQ:DKNG – Get Free Report) had its target price raised by equities research analysts at Stifel Nicolaus from ...
Stifel lowered the firm’s price target on Bumble (BMBL) to $6 from $7 and keeps a Hold rating on the shares. The company reported a slightly ...
While the scope of U.S.-imposed tariffs continues to expand, their impact on the economy remains uncertain, according to economists Lindsey Piegza and Lauren Henderson of Stifel, Nicolaus & Co. in ...
Stifel, which is in its 135th year in business, has more than 400 offices and 2,300 financial advisers nationwide.
ST. LOUIS, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.36 billion for the three months ended December 31, 2024, compared with $1.15 ...
Stifel Financial Corp. provides securities brokerage, investment banking, trading, investment advisory and related financial services. It operates through the following segments: Global Wealth ...
Stifel analyst Chris O’Cull lowered the firm’s price target on Wingstop (WING) to $375 from $400 and keeps a Buy rating on the shares. The ...
ST. LOUIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced the launch of Stifel Discover, a new Stifel-branded content feed available through its Wealth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results